Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karin Satra

Dermatology Ridgewood, NJ Medical Doctor

NPI 1619072303 CMS profile 1007119

400 Route 17 South, Ridgewood, NJ 07450

Open in the dashboard

General payments

$6,273

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karin Satra of Ridgewood, NJ is reported in the CMS Open Payments database as having received $6,273 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,455 29
2024 General $1,045 25
2023 General $1,429 22
2022 General $1,049 12
2021 General $716 13
2020 General $350 5
2019 General $229 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karin Satra
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Karin Satra were reported at $1,455. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Karin Satra Dermatology median Middle half National median
2019 $229 $454 $129–$1,240 $163
2020 $350 $235 $81–$756 $114
2021 $716 $377 $108–$1,108 $132
2022 $1,049 $514 $143–$1,391 $149
2023 $1,429 $607 $159–$1,674 $160
2024 $1,045 $751 $204–$1,903 $164
2025 $1,455 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,024 18 payments
  2. Janssen Biotech, Inc. $833 25 payments
  3. Novartis Pharmaceuticals Corporation $709 7 payments
  4. Lilly USA, LLC $476 5 payments
  5. Incyte Corporation $460 4 payments
  6. Sun Pharmaceutical Industries Inc. $309 7 payments
  7. Regeneron Healthcare Solutions, Inc. $272 5 payments
  8. Genzyme Corporation $265 4 payments
  9. Pfizer Inc. $251 6 payments
  10. E.R. Squibb & Sons, L.L.C. $246 2 payments
  11. Other $1,429 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,158 113 payments
  2. Education $115 2 payments
Products named General payments · program years 2019–2025
  1. Otezla $1,024 18 payments
  2. TREMFYA $930 25 payments
  3. OPZELURA $460 4 payments
  4. DUPIXENT $265 4 payments
  5. SOTYKTU $246 2 payments
  6. LIBTAYO $221 2 payments
  7. COSENTYX Immunology $207 2 payments
  8. CIBINQO $151 5 payments
  9. COSENTYX Dermatology $139 2 payments
  10. ACTHAR $135 1 payment
  11. Other $2,195 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

990

Median for Dermatology: 534

Drug cost

$501,986

Median for Dermatology: $67,151

Branded share of claims

18.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 13 $284,494
Taltz Autoinjector Ixekizumab Brand 18 $146,608
Jublia Efinaconazole Brand 25 $33,559
Opzelura Ruxolitinib Phosphate Brand 11 $20,282
Ketoconazole Generic 267 $4,043
Clobetasol Propionate Generic 59 $2,149
Ciclopirox Generic 43 $1,895
Metronidazole Generic 41 $1,729
Tacrolimus Generic 18 $1,092
Clindamycin Phosphate Generic 23 $1,050

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$327,743

Of which drugs: $12,225

Medicare patients

1,011

Average age 78

Services billed

15,251

619 women, 392 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 35%
Osteoporosis 27%
Cancer 23%
Diabetes 20%
Atrial fibrillation 20%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 26 9,200 $12,208
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 26 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $413
$413 — —
Otezla
  • Amgen Inc. $152
$152 — —
DUPIXENT
  • GENZYME CORPORATION $119
$119 — —
YCANTH
  • VERRICA PHARMACEUTICALS INC. $106
$106 — —
SKYRIZI
  • AbbVie, Inc. $33
$33 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record